GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » E10

PTGX (Protagonist Therapeutics) E10 : $-2.28 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Protagonist Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2025 was $-0.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2.28 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-07-06), Protagonist Therapeutics's current stock price is $51.05. Protagonist Therapeutics's E10 for the quarter that ended in Mar. 2025 was $-2.28. Protagonist Therapeutics's Shiller PE Ratio of today is .


Protagonist Therapeutics E10 Historical Data

The historical data trend for Protagonist Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics E10 Chart

Protagonist Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -2.29

Protagonist Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -2.55 -2.29 -2.28

Competitive Comparison of Protagonist Therapeutics's E10

For the Biotechnology subindustry, Protagonist Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Shiller PE Ratio falls into.


;
;

Protagonist Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagonist Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.19/134.9266*134.9266
=-0.190

Current CPI (Mar. 2025) = 134.9266.

Protagonist Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201506 -0.547 100.684 -0.733
201509 -0.592 100.392 -0.796
201512 -0.940 99.792 -1.271
201603 -2.003 100.470 -2.690
201606 -0.449 101.688 -0.596
201609 -0.870 101.861 -1.152
201612 -0.670 101.863 -0.887
201703 -0.840 102.862 -1.102
201706 -0.890 103.349 -1.162
201709 -0.290 104.136 -0.376
201712 -0.150 104.011 -0.195
201803 -0.360 105.290 -0.461
201806 -0.410 106.317 -0.520
201809 -0.380 106.507 -0.481
201812 -0.570 105.998 -0.726
201903 -0.580 107.251 -0.730
201906 -1.180 108.070 -1.473
201909 -0.610 108.329 -0.760
201912 -0.630 108.420 -0.784
202003 -0.720 108.902 -0.892
202006 -0.590 108.767 -0.732
202009 -0.210 109.815 -0.258
202012 -0.480 109.897 -0.589
202103 -0.540 111.754 -0.652
202106 -0.690 114.631 -0.812
202109 -0.700 115.734 -0.816
202112 -0.770 117.630 -0.883
202203 -0.430 121.301 -0.478
202206 -0.840 125.017 -0.907
202209 -0.640 125.227 -0.690
202212 -0.690 125.222 -0.743
202303 -0.670 127.348 -0.710
202306 -0.680 128.729 -0.713
202309 -0.580 129.860 -0.603
202312 0.440 129.419 0.459
202403 3.260 131.776 3.338
202406 -0.500 132.554 -0.509
202409 -0.540 133.029 -0.548
202412 1.980 133.157 2.006
202503 -0.190 134.927 -0.190

Add all the adjusted EPS together and divide 10 will get our e10.


Protagonist Therapeutics  (NAS:PTGX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Protagonist Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick director
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035